



B

Treatment	SUCRA	PrBest	Mean rank
Placebo	82.2	38.1	2.8
Met	81.2	9.9	2.9
TZD	69.2	22.8	4.1
Met+GLP-1RA	66.6	1.5	4.3
DPP4i	51.3	0.9	5.9
GLP-1RA	51.2	17.2	5.9
SU	50.2	0.0	6.0
Met+DPP4i	34.5	8.1	7.5
SGLT2i	25.7	0.8	8.4
DPP4i+SGLT2i	24.9	0.5	8.5
Met+TZD	12.8	0.2	9.7

Supplementary Fig. 8. Network geometry (A) and the results of rank test (B) for effect on low-density lipoprotein (LDL) cholesterol of antidiabetic treatments after 6 months. (A) Each circle represents an antidiabetic treatment that was included in the analysis, with the size of the circle proportional to the number of trials involving the treatment. The width of each connecting line is proportional to the number of subjects who participated in each pair of trials. The global test for inconsistency yielded a P value of <0.0001 , which suggests that there may be significant inconsistencies present in the network of treatments. (B) The table presents the results of the network rank test (surface under the cumulative ranking curve [SUCRA], probability of being the best [PrBest], mean rank) for different antidiabetic treatments, ordered by mean rank. (C) Network (upper right side) and pairwise (lower left side) meta-analytic results are depicted for effect on low-density lipoprotein cholesterol (mg/dL) of antidiabetic treatments after 6 months. The outcome of meta-analysis is expressed as effect size with 95% credible intervals in the case of network meta-analysis and 95% confidence intervals in the case of pairwise meta-analysis. Each value and interval refer to the efficacy of the top-row treatment compared to the left column. The order of antidiabetic treatments in this league table is presented in order of the mean rank results. TZD, thiazolidinedione; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; Met, metformin; SU, sulfonyleurea. ^aResults indicate statistical significance. (Continued to the next page)

Supplementary Fig. 8. Continued

C

	Met+TZD	DPP4i+SGLT2i	SGLT2i	Met+DPP4i	SU	GLP-1RA	DPP4i	Met+GLP-1RA	TZD	Met	Placebo	
Met+TZD	Met+TZD	-3.5 (-18.6 to 11.4)	-3.6 (-18.6 to 11.4)	-4.8 (-23.9 to 14.4)	-9.6 (-19.9 to 0.8)	-9.2 (-28.3 to 9.9)	-9.0 (-21.3 to 3.3)	-11.6 (-22.0 to -1.2)	-12.6 (-27.1 to 2.0)	-1.6 (-4.1 to 0.9)	-14.5 [*] (-27.8 to -1.2)	
DPP4i+SGLT2i		DPP4i+SGLT2i	0.0 (-7.0 to 7.0)	-1.2 (-20.9 to 18.5)	-6.0 (-17.3 to 5.3)	-5.6 (-25.2 to 14.0)	-5.4 (-14.0 to 3.2)	-8.0 (-19.4 to 3.4)	-9.0 (-24.2 to 6.2)	-13.2 (-23.3 to -3.1)	-10.9 (-23.1 to 1.3)	
SGLT2i		0.0 (-7.0 to 7.0) <i>I</i> ² =0.0% 1 study	SGLT2i	-1.2 (-20.9 to 18.5)	-6.0 (-17.3 to 5.3)	-5.6 (-25.2 to 14.0)	-5.4 (-14.0 to 3.2)	-8.0 (-19.4 to 3.4)	-9.0 (-24.2 to 6.2)	-9.6 (-20.7 to 1.5)	-10.9 (-23.1 to 1.3)	
Met+DPP4i				SGLT2i	-4.8 (-21.2 to 11.6)	-4.4 (-27.4 to 18.6)	-4.2 (-21.9 to 13.5)	-6.8 (-23.3 to 9.7)	-7.8 (-27.1 to 11.5)	15.3 (-2.4 to 33.0)	-9.7 (-28.2 to 8.8)	
SU					SU	0.4 (-16.0 to 16.8)	0.6 (-6.8 to 8.0)	-2.0 (-5.4 to 1.4)	-3.0 (-13.7 to 7.7)	-5.2 (-24.2 to 13.8)	-4.9 (-13.9 to 4.1)	
GLP-1RA						GLP-1RA	0.2 (-17.5 to 17.9)	-2.4 (-18.8 to 14.0)	-3.4 (-22.7 to 15.9)	-4.5 (-12.4 to 3.5)	-5.3 (-23.7 to 13.1)	
DPP4i		5.4 (-3.2 to 14.0) <i>I</i> ² =0.0% 1 study	1.4 (-1.9 to 4.3) <i>I</i> ² =0.0% 2 studies	-11.1 [*] (-18.0 to -4.2) <i>I</i> ² =0.0% 1 study				DPP4i	-2.6 (-10.1 to 4.9)	-3.6 (-16.2 to 9.0)	14.6 (-0.1 to 29.3)	-5.5 (-14.2 to 3.2)
Met+GLP-1RA								Met+GLP-1RA	-1.0 (-11.8 to 9.8)	-8.4 (-24.7 to 7.9)	-2.9 (-12.0 to 6.2)	
TZD	-2.0 (-12.7 to 8.7) <i>I</i> ² =0.0% 1 study				-3.2 [*] (-5.4 to -0.9) <i>I</i> ² =13.0% 3 studies				TZD	-4.0 (-20.2 to 12.2)	-1.9 (-15.5 to 11.7)	
Met	6.3 (-1.0 to 13.7) <i>I</i> ² =55.7% 3 studies			-4.6 (-10.9 to 1.8) <i>I</i> ² =65.3% 2 studies	4.0 [*] (1.7 to 6.2) <i>I</i> ² =40.1% 3 studies	4.0 (-12.2 to 20.2) <i>I</i> ² =0.0% 1 study	7.7 [*] (4.4 to 11.0) <i>I</i> ² =0.0% 3 studies	1.6 (-0.9 to 4.1) <i>I</i> ² =0.0% 1 study	1.1 (-0.6 to 2.9) <i>I</i> ² =89.2% 5 studies	Met	4.2 (-2.8 to 11.2)	
Placebo			4.5 [*] (1.9 to 7.0) <i>I</i> ² =0.0% 5 studies	-5.6 (-14.2 to 3.0) <i>I</i> ² =0.0% 1 study			0.8 (-1.9 to 3.6) <i>I</i> ² =34.4% 7 studies		-0.1 (-17.8 to 17.6) <i>I</i> ² =0.0% 1 study	-0.2 (-8.0 to 7.6) <i>I</i> ² =0.0% 2 studies	Placebo	